Giant cell glioblastoma

Giant cell glioblastoma (GCG) is a rare histological variant of glioblastoma (WHO grade IV), the most aggressive primary brain tumor. It is classified as an IDH-wildtype glioblastoma and is characterized by the predominance of bizarre, multinucleated giant cells within the tumor tissue. This tumor arises from glial cells in the brain and primarily affects the central nervous system. Giant cell glioblastoma accounts for approximately 1–5% of all glioblastomas and tends to occur in a slightly younger patient population compared to conventional glioblastoma. Key symptoms depend on the tumor's location within the brain and may include persistent headaches, seizures, progressive neurological deficits (such as weakness, speech difficulties, or vision changes), cognitive decline, personality changes, nausea, and vomiting due to increased intracranial pressure. The tumor most commonly arises in the cerebral hemispheres, particularly the temporal and parietal lobes, and can grow rapidly with surrounding edema. The current treatment approach mirrors that of conventional glioblastoma and typically involves maximal safe surgical resection followed by concurrent radiation therapy and temozolomide chemotherapy (the Stupp protocol). Despite aggressive treatment, prognosis remains poor, though some studies suggest that giant cell glioblastoma may carry a slightly better prognosis compared to conventional glioblastoma, possibly due to its more circumscribed growth pattern, higher rates of TP53 mutations, and lower frequency of EGFR amplification. Recurrence is common, and clinical trials investigating novel therapies including immunotherapy and targeted agents may be available for eligible patients. Supportive care, including corticosteroids for edema management and antiepileptic medications, plays an important role in symptom control.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Giant cell glioblastoma